Related Experiment Video
Updated: Dec 3, 2025
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
ERCC1 expression and platinum chemosensitivity in patients with ovarian cancer: A meta-analysis
Chunjie Zhang1, Shan Gao2, Jingwen Hou3
1Gynecology Unit II, Gansu Provincial Maternity and Child-care Hospital, Lanzhou, Gansu, China.
Objective:
This study aimed to comprehensively investigate the correlation of ERCC1 expression and chemosensitivity of ovarian cancer.
Methods:
The literature on the relationship between the excision repair cross complementary gene 1 (ERCC1) and the chemosensitivity of ovarian cancer published in PubMed, Web of Science, EMBASE, CNKI, and the China Wanfang database from the establishment of the databases to June 2020 were searched. Chemosensitivity is evaluated by clinical effective rate (complete remission plus partial remission). Statistical analysis was carried out by using Stata 15.1 software.
Results:
A total of 11 articles met the inclusion criteria, consisting of 758 patients with ovarian cancer. The results showed a significant difference in chemosensitivity between the low expression group and the high expression group of ERCC1 (odds ratio 4.23; 95% confidence interval 2.96, 6.06; P < 0. 01). The same result was shown in the ethnicity subgroup.
Conclusion:
The chemosensitivity of ovarian cancer patients with a low expression of ERCC1 is better than that of patients with a high expression.
